Dermata Stock Jumps On Positive Psoriasis Candidate Data

Dermata Therapeutics Inc DRMA announced topline results from its Phase 1b trial of DMT310 for mild-to-moderate psoriasis.
The percentage of treatment responders in Physician's Global Assessment (PGA) with a score of 0 or 1 was 29.6% at Week 8. PGA is a scoring system used to assess disease severity.
The percentage of patients with a score of 0 or 1 in the total Psoriasis Area Severity Index (PASI) was 25.9% at Week 8.
Treatment with DMT310 resulted in a change from baseline in pruritis of -19.6% for the target lesion at Week 8.
DMT310 appeared to be safe, with only three reported adverse events (AEs). Only two of the three AEs evaluated as related to treatment, and no reported serious adverse events.
DMT310 is Dermata's lead product candidate, which incorporates the proprietary, multifaceted, Spongilla technology to treat various dermatological conditions topically.
Related: Why Are Dermata Therapeutics Shares Trading Higher Today?
Price Action: DRMA shares are up 9.32% at $4.81 during the premarket session on the last check Tuesday.